Abcam, a UK-based provider of life-science research tools, has named Tommy Thomas as its new vice president of IR. He will be based in the company’s Waltham, Massachusetts office.
Thomas joins from Avantor, another provider to the healthcare sector, where he also served as vice president of IR. Prior to that, he spent several years at Perkin Elmer, first as vice president of IR and later as CFO for the company’s global services business.
Before moving into the IR profession, Thomas worked for eight years at TIAA-CREF, the US financial services organization with more than $1 tn in assets under management, as a buy-side analyst covering medical technology and life-science tools.
‘Deep industry experience’
‘I am delighted to have Tommy joining us. His deep industry experience, significant investor relations expertise and strong institutional investor and research analyst relationships are a major step forward for us,’ says Michael Baldock, Abcam’s CFO, in a statement.
‘Tommy will be a real asset to Abcam and our investors as we continue to grow, differentiate ourselves in the marketplace, and deliver value for all our stakeholders.’
Thomas adds: ‘I am very pleased to join Abcam at this important time in its evolution. The company’s customer-centric model focusing on new product innovation for researchers and clinicians in the life sciences industry is highly differentiated. I look forward to learning and telling our story as I build new friendships along the way.’
